https://www.selleckchem.com/pr....oducts/Pomalidomide(
1% versus 7.9%, p = 8.629e-09). Among 26 candidate genes, the prevalence rate of PDVs in five genes showed a statistically significant difference between patients and controls (33 out of 235 versus 1 out of 241, p = 4.533e-1, including ATXN2 (p = 0.0033), TXNRD2 (p = 0.019, MYOC (p = 0.014, FOXC1 (p = 0.014, and CDKN2B (p = 0.0287). Furthermore, two sisters harboring a stop-loss mutation EFEMP1 p.Ter494Glu were found in the POAG cohort, and further analysis of the family strongly suggested that EFEMP1 p.Ter494Glu w
Like
Comment
Share
